基于瘤内影像组学特征映射的可解释机器学习用于局部晚期鼻咽癌辅助化疗患者分层
本研究回顾性纳入397例局部晚期鼻咽癌患者,从治疗前增强T1加权MRI的原发肿瘤大体体积中提取影像组学特征,发现3 mm-sigma LoG滤波图像的gldm_DependenceVariance特征可定义高风险亚组;该亚组中接受同步放化疗联合辅助化疗者3年无病生存率为90%,而单纯同步放化疗者为57%(HR 0.20,95%CI 0.05-0.94,P=0.007)。
要点
- 治疗前增强T1加权MRI中3 mm-sigma LoG滤波图像的gldm_DependenceVariance特征可识别辅助化疗获益的高风险亚组。
- 该特征定义的高风险组中,同步放化疗联合辅助化疗者3年无病生存率90%,单纯同步放化疗者57%。
- 该特征的预测价值可推广至其对应的预测亚体积,多因素HR为0.27(P=0.017)。
核心结论
- 该影像组学特征及其异质性映射可能成为临床实践中可靠的、可解释的辅助化疗决策工具。
研究设计与样本
- 回顾性研究,纳入397例局部晚期鼻咽癌患者,收集治疗前增强T1加权MRI、临床变量及随访资料,从原发肿瘤大体体积(GTVnp)中识别单个体素级影像组学特征并定义预测亚体积,独立验证该特征及亚体积的预测价值。
关键影像表现/征象
- 从原发肿瘤大体体积中仅识别出一个影像组学特征,即3 mm-sigma LoG滤波图像的gldm_DependenceVariance。
- 通过体素级特征映射在GTVnp内定义预测亚体积,该亚体积的预测价值可独立验证。
诊断标准与关键数值
- 高风险组中,同步放化疗联合辅助化疗者3年无病生存率90%,单纯同步放化疗者57%(HR 0.20,95%CI 0.05-0.94,P=0.007)。
- 多因素分析显示,同步放化疗联合辅助化疗者较单纯同步放化疗者的无病生存HR为0.21(95%CI 0.06-0.68,P=0.009)。
- 该特征对应预测亚体积的多因素无病生存HR为0.27(P=0.017)。
临床应用与阅片要点
- 作者认为,该特征及其异质性映射可能成为临床实践中可靠的、可解释的辅助化疗决策工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This study aimed to discover intra-tumor heterogeneity signature and validate its predictive value for adjuvant chemotherapy (ACT) following concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal carcinoma (LA-NPC).
MATERIALS AND METHODS: 397 LA-NPC patients were retrospectively enrolled. Pre-treatment contrast-enhanced T1-weighted (CET1-w) MR images, clinical variables, and follow-up were retrospectively collected. We identified single predictive radiomic feature from primary gross tumor volume (GTVnp) and defined predicted subvolume by calculating voxel-wised feature mapping and within GTVnp. We independently validate predictive value of identified feature and associated predicted subvolume.
RESULTS: Only one radiomic feature, gldm_DependenceVariance in 3 mm-sigma LoG-filtered image, was discovered as a signature. In the high-risk group determined by the signature, patients received CCRT + ACT achieved 3-year disease free survival (DFS) rate of 90% versus 57% (HR, 0.20; 95%CI, 0.05-0.94; P = 0.007) for CCRT alone. The multivariate analysis showed patients receiving CCRT + ACT had a HR of 0.21 (95%CI: 0.06-0.68, P = 0.009) for DFS compared to those receiving CCRT alone. The predictive value can also be generalized to the subvolume with multivariate HR of 0.27 (P = 0.017) for DFS.
CONCLUSION: The signature with its heterogeneity mapping could be a reliable and explainable ACT decision-making tool in clinical practice.
引用
- Teng, Zhang, Han, et al. Explainable machine learning via intra-tumoral radiomics feature mapping for patient stratification in adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Radiol Med. 2023. PMID: 37300736. doi:10.1007/s11547-023-01650-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。